The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MBRX | -81.92% | -99.34% | -63.39% | -100% |
| S&P | +14.49% | +91.09% | +13.83% | +225% |
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 6.5% |
| Market Cap | $7.28M | -10.6% |
| Market Cap / Employee | $0.43M | 0.0% |
| Employees | 17 | -5.6% |
| Net Income | -$7.64M | -76.9% |
| EBITDA | -$5.69M | 7.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.56M | -30.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.29M | -30.5% |
| Short Term Debt | $0.13M | 14.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -112.58% | -43.3% |
| Return On Invested Capital | -125.42% | -52.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.58M | 6.4% |
| Operating Free Cash Flow | -$5.58M | 6.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.41 | 0.68 | 0.55 | 101.65 | 26869.97% |
| Price to Tangible Book Value | 1.11 | -1.39 | -0.64 | -0.38 | -149.27% |
| Enterprise Value to EBITDA | -0.23 | -0.29 | -0.31 | 0.43 | 94.66% |
| Return on Equity | -141.5% | -135.8% | -214.8% | -503.8% | 480.25% |
| Total Debt | $0.51M | $0.48M | $0.45M | $0.42M | -21.05% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
